Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy

Climens, Aude Roborel de; Tunceli, Kaan; Arnould, B; Germain, N.; Iglay, Kristy; Norquist, Josephine M.; Brodovicz, Kimberly G.

doi:10.1185/03007995.2015.1020364

Cited by 25 publications

(38 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was attributed to success of the removable partial denture (RPD) therapy in both groups; however, better outcomes (lower OHIP-14 score) were obtained among the PA-RPD patients compared to the C-RPD) patients. These results are in line with several studies which used different patients' self-reported measures including the OHIP-14 questionnaire [14,18,[20][21][22][23][24].…”

Section: Discussionsupporting

confidence: 90%

Treatment Outcomes Based on Patient’s Oral Health Related Quality of Life (OHRQoL) after Receiving Conventional Clasp or Precision Attachment Removable Partial Dentures in Distal Extension Cases: A Randomized Controlled Clinical Trial

Mamdouh

El-Sherbini

Mady

2019

BDS

View full text Add to dashboard Cite

Purpose: To compare the effect of two treatment options in mandibular Kennedy class I cases regarding oral health related quality of life (OHRQoL) and the biting force, removable partial dentures retained by either precision attachment (PA-RPD) or clasps (C-RPD)Materials and methods: The study included 32 partially edentulous patients which 16 patients received PA-RPD (OT Cap Attachment) and 16 patients received C-RPD. All the patients in both groups were asked to fill the OHRQoL questionnaire after 1 week (baseline), 3 months, 6 months and 12 months after prosthesis insertion. Biting force was measured using the i-load Star Sensor one week, 3 months, 6 months and 1 year after partial denture insertion for all patients in both groups. Statistical analysis comprised Mann Whitney U test, Friedman’s test, Dunn’s test and Chi-square test.Results: The results of OHRQoL revealed that at the baseline, 3 months and 6 months the PA-RPD showed statistically significant lower mean total OHIP-14 score than the C-RPD. However, after 12 Monthes , there was no statistically significant difference between total OHIP-14 scores in the two groups. Concerning the biting force there was no statistically significant difference between the two groups.Conclusion: Within the limitations of this study it was concluded that the OHRQoL of both the PA-RPD and the C-RPD was comparable after 12 months. Similarly the biting force was the same for both treatment options.

show abstract

Section: Discussionsupporting

confidence: 90%

Treatment Outcomes Based on Patient’s Oral Health Related Quality of Life (OHRQoL) after Receiving Conventional Clasp or Precision Attachment Removable Partial Dentures in Distal Extension Cases: A Randomized Controlled Clinical Trial

Mamdouh

El-Sherbini

Mady

2019

BDS

View full text Add to dashboard Cite

show abstract

“…However, the outcome of diabetes treatments should not be evaluated only by HbA1c levels as the evaluation of the psychological aspects of patients, including treatment satisfaction, wellbeing and quality of life (QOL), are also important, which are referred to as patient-reported outcomes (PROs) ( Table 1 ) [ 6 , 7 , 8 , 9 ]. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a questionnaire used to assess patients’ satisfaction with their diabetes treatment [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes

Saisho

2018

IJERPH

View full text Add to dashboard Cite

The efficacy of diabetes treatment should not be evaluated solely by HbA1c levels as they should also focus on patient-reported outcomes (PROs), such as patient satisfaction, wellbeing and quality of life. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) has been developed to assess patient satisfaction with diabetes treatment. DTSQ has been translated into more than 100 languages and is widely used in many countries, since it is relatively easy to answer and is used for both patients with and without medical therapy. Novel therapeutic options, such as insulin analogs, incretin-based therapy and sodium-glucose cotransporter 2 (SGLT2) inhibitors, have been shown to improve patient satisfaction using DTSQ for assessments. DTSQ is not only used for comparisons between different medications or treatment strategies, but also can be used to assess the quality of diabetes care in clinical settings. This is important as an improvement in treatment satisfaction may enhance patients’ self-efficacy and adherence to therapy, leading to the achievement of long-term stable glycemic control and reduced risk of diabetic complications. In this review, we summarize the current topics in DTSQ, introducing our own experience, and discuss the role of PROs in diabetes treatment.

show abstract

“…Treatment satisfaction and health-related quality of life (HRQOL) are important for successful treatment of diabetes [ 17 ]. It has been reported that improved quality of life (QOL) results in improved adherence with medication [ 18 ] and poor adherence contributes to poor glycemic control [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

“…It consists of 3 subscales, “treatment convenience”, “somatic symptom” and “satisfaction”. The OHA-Q is the only satisfaction instrument that specific to oral hypoglycemic treatment [ 17 ]. It can evaluate treatment satisfaction, including unique side effects to OHA.…”

Section: Introductionmentioning

confidence: 99%

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Nakajima

Okada

Mohri

et al. 2018

Diabetol Metab Syndr

View full text Add to dashboard Cite

BackgroundThe benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria, or volume depletion. It is not clear whether dapagliflozin, an SGLT2 inhibitor, improves treatment satisfaction among patients in a comprehensive way despite the negative side effects. This study assessed the effect of dapagliflozin on glycosylated hemoglobin (HbA1c), body weight, and treatment satisfaction in overweight patients with type 2 diabetes mellitus treated with oral hypoglycemic agents.MethodsThis multicenter, open-label, single-arm observational study included patients with type 2 diabetes mellitus administering dapagliflozin 5 or 10 mg per day for 14 weeks. Changes in treatment satisfaction were evaluated using a new version of the Oral Hypoglycemic Agent-Questionnaire (OHA-Q ver. 2) consisting of 23 items. Correlation between treatment satisfaction and HbA1c levels and body weight were analyzed using the Spearman’s rank-correlation coefficient.ResultsOf the 221 patients enrolled, 188 completed the study. Mean HbA1c decreased from 7.8 ± 0.7% (62.1 ± 7.5 mmol/mol) to 7.3 ± 0.8% (55.9 ± 8.7 mmol/mol) (change − 0.6 ± 0.7%, P < 0.001) and body weight decreased from 82.5 ± 14.6 to 80.7 ± 14.8 kg (change − 2.3 ± 2.8 kg, P < 0.001). OHA-Q ver. 2 was validated as well, the mean OHA-Q ver. 2 total score increased from 44.3 ± 9.4 to 46.6 ± 9.8 (best score 69, worst score 0; change 2.3 ± 6.6, P < 0.001). The change in body weight significantly correlated with the OHA-Q ver. 2 total score (Spearman’s ρ = − 0.17, P = 0.035). The change in HbA1c levels significantly correlated with the satisfaction subscale score (Spearman’s ρ = − 0.19, P = 0.011).ConclusionsDapagliflozin significantly improved treatment satisfaction among patients with type 2 diabetes mellitus for 14 weeks. Body weight loss significantly correlated with treatment satisfaction.Trial registration UMIN-CTR: UMIN000016304Electronic supplementary materialThe online version of this article (10.1186/s13098-018-0313-x) contains supplementary material, which is available to authorized users.

show abstract

Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy

Cited by 25 publications

References 104 publications

Treatment Outcomes Based on Patient’s Oral Health Related Quality of Life (OHRQoL) after Receiving Conventional Clasp or Precision Attachment Removable Partial Dentures in Distal Extension Cases: A Randomized Controlled Clinical Trial

Treatment Outcomes Based on Patient’s Oral Health Related Quality of Life (OHRQoL) after Receiving Conventional Clasp or Precision Attachment Removable Partial Dentures in Distal Extension Cases: A Randomized Controlled Clinical Trial

Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Contact Info

Product

Resources

About